奥地利当地时间12月3日～7日，2016年国际肺癌研究学会（IASLC）年会暨第17届世界肺癌大会（WCLC）将在奥地利维也纳如期举行。今年，《中国医学论坛报》编辑，带着对会议内容的期待，和与会的专家一起为您带来大会最新、最热最有价值的肺癌研究、新闻及资讯。敬请关注《中国医学论坛报》专题系列报道。

本次大会中，中国大陆、台湾及香港地区共计34项研究入围了口头报告，其中，广东省人民医院、广东省肺癌研究所吴一龙教授的研究“BRAIN: A Phase – Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)”更入选了大会的主席研讨会，充分展现了我国原创研究的力量与风采。除了这些入选口头报告的研究，我国肺癌领域的多位专家学者也受邀在大会的诸多环节发表演说、分享经验，都非常值得期待。《中国医学论坛报》编辑根据目前已发布的日程，将入选大会口头报告（oral session，mini oral session）的研究进行了梳理，以飨读者。

12月3日

WARDROBE OPEN

Foyer D

Exit U2 Station ‘Krieau’

• 13:30 WS02.16: The Shanghai Screening Trial

  Liu Shi-Yuan, China

12月4日

Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against Lung Cancer Session

ROOM: STOLZ 1

• 08:30 JCES01.03: Perspectives on Precision Medicine for Early Stage NSCLC

  Jie Hu, Zhongshan Hospital Fudan University, China

• 08:50 JCES01.04: Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC

  Qing Zhou, Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

• 09:10 JCES01.05: New Clinical Trials on Gene Alteration in China

  Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China

• 10:30 JCES01.09: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR–TKI Resistance

  Wenxian Wang, Zhejiang Cancer Hospital, China

• 10:40 JCES01.10: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer

  Yue Zhao, Fudan University Shanghai Cancer Center,China

• 10:50 JCES01.11: Altered Expression of Programmed Death–Ligand 1 after Neo–Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

  Zhengbo Song, Zhejiang Cancer Hospital, China

12月5日

OA07: Lymph Node Metastases and Other Prognostic Factors for Local Spread

ROOM: STOLZ 1

• 14:30 OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis

  Nan Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

OA08: Targeted Therapies in Brain Metastases

ROOM: SCHUBERT 1, LEVEL ONE

• 16:00 OA08.01: Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid

  Yun Fan, Zhejiang Cancer Hospital, China

MA02: RNA in Lung Cancer

ROOM: STOLZ 2

• 15:14 MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC

  Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

MA03: Epidemiology, Risk Factors and Screening

ROOM: LEHAR 3–4

• 14:32 MA03.03: High Risk for Second Primary Lung Cancer in Taiwanese Early–Onset Female Breast Cancer Patients

  Pei–Ying Lin, National Taiwan University Hospital,Taiwan

MA04: HER2, P53, KRAS and Other Targets in Advanced NSCLC

ROOM: LEHAR 3–4

• 16:12 MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC

  Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China

MA06: Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices

ROOM: STRAUSS 2

• 16:36 MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non Small Cell Lung Cancer

  Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

MA05: Innovative Techniques in Pulmonology and the Impact on Lung Cancer

ROOM: STRAUSS 1

• 17:00 MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis

  Jiancheng Li, Fujian Cancer Hospital, China

12月6日

PL03: Presidential Symposium

ROOM: HALL D (PLENARY HALL)

• 09:25 PL03.05: BRAIN: A Phase – Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)

  Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academyof Medical Sciences, China

OA09: Locally Advanced NSCLC:Innovative Treatment Strategies

ROOM: STRAUSS 3

• 11:20 OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo–Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC

  Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

• 12:05 OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced? Technologies Benefit Stage NSCLC Treated with CCRT

  Baosheng Li, Shandong Cancer Hospital, China

OA11: Angiogenesis in Advanced Lung Cancer

ROOM: STOLZ 2

• 11:20 OA11.03: A Randomized, Multi–Center, Double–Blind Phase II Study of Fruquintinib in Patients with Advanced Non–Small Cell Lung Cancer

  Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

• 12:05 OA11.07: Combining Anti–Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

  Sha Zhao, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine,China

OA12: SBRT and Other Issues in Early Stage NSCLC

ROOM: STRAUSS 2

• 11:45 OA12.05: Noninvasive CT–Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma

  Dawei Yang, Zhongshan Hospital Fudan University, China

MA08: Treatment Monitoring in Advanced NSCLC

ROOM: LEHAR 3–4

• 11:12 MA08.03: Osimertinib vs Platinum–Pemetrexed for T790M–Mutation Positive Advanced NSCLC (AURA3):Plasma ctDNA Analysis

  Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

• 11:30 MA08.05: Depth of Response to First–Line EGFR TKI Does Not Predict Survival in EGFR–Mutated NSCLC Patients

  Ting–Hui Wu, National Taiwan University Hospital,Taiwan

• 11:42 MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)

  Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

MA10: Facing the Real World: New Staging System and Response Evaluation in Immunotherapy

ROOM: STOLZ 2

• 14:20 MA10.01: Validations of the 8th AJCC/UICC Lung Cancer Staging System in a Large North America Cohort

  Lin Yang, Cancer Hospital,Chinese Academy of Medical Sciences, China

MA11: Novel Approaches in SCLC and Neuroendocrine Tumors

ROOM: STRAUSS 3

• 14:20 MA11.01: Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture–Based Targeted Sequencing

  Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

• 15:20 MA11.09: Progastrin–Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)

  Xiaotong Zhang, Peking Union Medical College Hospital (PUMCH), China

12月7日

OA19: Translational Research in Early Stage NSCLC

ROOM: SCHUBERT 3

• 11:20 OA19.03: Identify Lung Adenocarcinoma in Situ Among Pulmonary Micro–Nodules Through Blood Gene Expression Profiles

  Baohui Han, Shanghai Chest Hospital, China

OA21: Palliative and Supportive Care for Lung Cancer Patients

ROOM: SCHUBERT 5

• 11:00 OA21.01: Pooled Analysis of the Incidence and Risk of Treatment–Related Pneumonitis with Anti–PD–1/PD–L1 Therapies in Cancer Patients

  Shaodong Hong, Sun Yat–sen University Cancer Center,China

MA15: Immunotherapy Prediction

ROOM: SCHUBERT 1, LEVEL ONE

• 14:32 MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD–1 Blockade in Advanced NSCLC

  Weijing Cai, Shanghai Pulmonary Hospital, China

• 15:26 MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD–1 Blockade Immunotherapy in Lung Adenocarcinoma

  Zhong–Yi Dong, Guangdong Lung Cancer Institute,Guangdong General Hospital, China

MA16: Novel Strategies in Targeted Therapy

ROOM: STRAUSS 2

• 14:56 MA16.06: Phase I/II Study of AC0010, Mutant–Selective EGFR Inhibitor, in Non–Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

  Yi Long Wu, Guangdong Lung Cancer Institute,Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

MA17: Genetic Drivers

ROOM: LEHAR 1–2

• 14:32 MA17.03: Identifying Genomic Alteration and Inter–Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA

  Kezhong Chen, Peking University People’s Hospital,China

• 14:50 MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas

  Hao–ran Zhai, Guangdong Lung Cancer Institute,Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China

• 15:32 MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non–Small Cell Lung Cancer

  Shuang Zhao, Department of Respiratory Medicine,West China Hospital, Sichuan University, Chengdu610041, China., China